Table 2 Prognostic biomarkers detected by array CGH in 18 cases of ovarian cancer correlated with clinical information
Study # | High risk biomarkers | Disease summary and current status |
|---|---|---|
OC-1 | MYC | Stage IIIC/serous; Locally advanced disease |
OC-2 | None detected | Stage IIIC/serous; Disease free under surveillance |
OC-3 | KRAS, CCND2, | Stage IIIC/serous; Non-resectable disease; progressive |
OC-4 | CCNE1, CCND1, CCND3, MYC, ETV6 | Stage IIIC/clear cell; Progressive non-resectable disease |
OC-5 | None detected | Stage 1C/granulosa; Disease free under surveillance |
OC-6 | None detected | Stage IIA/serous; Disease free under surveillance |
OC-7 | CCND3, MYC, AKT2, | Stage IIIC/serous; Locally recurrent disease |
OC-8 | MYC, JAK2, FGFR3, MYB | Stage IIB/serous; Stable disease following surgery for recurrence |
OC-9 | CCNE1, MYC, ETV6 | Stage IV at diagnosis; Metastatic to brain; deceased June 2012 |
OC-10 | PLAG1 | Stage IIIC/serous; Recurrent disease |
OC-11 | None detected | Stage IIIC/serous; Progressive disease |
OC-12 | None detected | Stage IIIC/serous; Metastatic disease |
OC-13 | ERBB2 (HER2) | Stage IV serous/Metastatic to bones and chest; Platinum resistant |
OC-14 | CCNE1 | Stage III/serous; Progressive local recurrence |
OC-15 | None detected | Stage 1A/serous; Disease free under surveillance |
OC-16 | MYC | Stage IIIC/serous; Locally advanced disease |
OC-17 | PAK1 | Stage IIIC/serous; Recurrent disease |
OC-18 | PTEN deletion | Stage IIIC/serous; Progressive non-resectable disease |